Skip to main content
. 2022 Dec 9;14:453–463. doi: 10.2147/BCTT.S389696

Figure 1.

Figure 1

The decision tree and partitioned survival model structure overview for HER2-low breast cancer patients. Group 1 represents overall patients, which includes HR-positive and HR-negative patients. Group 2 represents the HR-positive patients. The intervention and comparator of each group is T-DXd and chemotherapy, respectively. The PartSA containes three health states: progression-free, progressed disease and death.

Abbreviations: PartSA, partitioned survival approach; HR+, hormone receptor–positive; T-DXd, trastuzumab deruxtecan.